What Is ARA-290?
What Is ARA-290?
ARA-290 is a small peptide derived from erythropoietin (EPO) — a hormone naturally produced by the kidneys. Unlike EPO itself, ARA-290 is designed to target only the tissue-protective properties of EPO without stimulating red blood cell production.
How Does It Work?
ARA-290 binds to receptors involved in tissue protection and inflammation control. Researchers are studying its potential to reduce inflammatory nerve damage and support healing in peripheral nerve conditions.
Educational Video
Educational Video Coming Soon
We are producing educational videos for every peptide in the Mana Health Peptide Library. This video will be available soon.
Potential Benefits
The following represents areas of active research — not confirmed medical benefits. This is educational information only.
Things To Know
Possible Side Effects
Generally well-tolerated in published studies. No significant hematological effects noted. Consult a healthcare professional.
Current Research
ARA-290 has been studied in clinical trials for conditions including sarcoidosis-associated neuropathy and type 2 diabetes with neuropathy, with published peer-reviewed results.
Frequently Asked Questions
Safety profiles for ARA-290 are still being established. Always consult a qualified healthcare professional before making any health decisions. This information is for educational purposes only.
Explore the related health categories, search our Health Library, or speak with a qualified healthcare professional for personalized guidance.
The Bottom Line
ARA-290 is an active area of peptide research with growing scientific interest. Like all research peptides, it should be understood in an educational context. Health decisions should always be made with a qualified healthcare professional who understands your individual situation.